

Research & Development Fact Sheet

Bilcare Research (BSE: BIL) provides integrated R&D consultancy and outsourcing solutions to the global pharmaceutical industry. We provide solutions in the critical areas of brand protection, brand management technologies, clinical supplies and next generation packaging solutions.

Our commitment to R&D emanates from our goal to develop products that are essential for the long-term success of the pharmaceutical industry and improving patient outcomes.



R&D Philosophy

Bilcare Research's R&D efforts are geared to address the challenges of the 5 Cs viz., Compliance, Counterfeiting, Communication, Convenience and Cost. We partner with pharmaceutical majors to ensure scientific optimization, better shelf life, increased product stability, ease of distribution and brand protection with significant cost reduction.

Achievements for the year 08-09

- Design and development of "Greenpack" systems-eco-friendly packaging materials for packaging of pharmaceutical products
- Enhancing the Nonclonable™ Technology offering for addressing Drug diversion, secure supply chain and anytime anywhere identity & authenticity of the product
- Development of novel lockable and self enclosable packaging systems
- Development of Restricted product / multi-functional access package system
- Novel Image embedded packaging materials
- Specialized inks and marker technologies for the Flexography technology system

Advisory Board

[Dr. John LaMattina](#)

Dr. John LaMattina is the Chairman of the Corporate Advisory Board at Bilcare Global Clinical Supplies (GCS). He is responsible for endowing the team with independent scientific industry proficiency. His expertise has proved to be an asset to the research and innovation initiatives at Bilcare. Dr. LaMattina previously served as the Senior Vice President of Pfizer Inc.

[Dr. Arthur Carty](#)

Dr. Arthur Carty is the board member of the Corporate Advisory Board at Bilcare Global Clinical Supplies (GCS). He provides technology and biotech expertise to Bilcare GCS. Dr. Carty was the first Executive Director of the Waterloo Institute of Nanotechnology and former National Science Advisor to Canada's Prime Minister.

Patents

- 32 Patent applications globally
- 9 Patents granted
- Over 136 patents filings worldwide

R&D Centers

Bilcare Research has four R&D centers worldwide with a total strength of 40 scientists. All Bilcare Research plants and R&D centers are FDA/DEA registered, controlled and are in classified areas.

India

- Global Center Of Excellence
- Material Science Research Center
- Optima – Patented module on optimum packaging and stability
- 1st Clinical trial services facility in Asia
- DSIR approved research facility
- Winner of the OPPI "Best Vendor" award for 2 consecutive years
- Winner of the 'Outstanding Innovation of the Year' award by Chemtech Foundation

United Kingdom

- Clinical trial services facility
- MHRA approved site

USA

- Clinical trial services facility
- 14 acre FDA & DEA approved site
- Films & foils secondary production

Singapore

- Material Science Research Centre
- R&D center for Bilcare Technology

Customers

Bilcare Research caters to over 500 pharmaceutical companies worldwide including Novartis, Ranbaxy, Johnson & Johnson, Merck, Pfizer, Wyeth, Glaxo Smithkline and Sanofi Aventis.

Research & Operations	Regional Offices	Representative Offices
<p>Bilcare Singapore Pte. Ltd. 52 Changi South Street 1 Singapore 486161 direct-sg@bilcare.com</p> <p>Bilcare Limited 1028 Shiroli, Rajgurunagar Pune 410505 direct-in@bilcare.com</p> <p>Bilcare Inc 300 Kimberton Road Phoenixville PA 19460 direct-us@bilcare.com</p> <p>Bilcare GCS (Europe) Ltd Waller House, Elvicta Business Park, Crickhowell Powys NP8 1DF UK. direct-europe@bilcare.com</p>	<p>Bilcare Room 701, No.89 Xing Tai Road Baiyu District, Guangzhou direct-ch@bilcare.com</p> <p>Bilcare GmbH Industriepark Höchst 65926 Frankfurt Main direct-eu@bilcare.com</p> <p>Bilcare Marketing America Latina Ltda. Alameda Campinas 834 - Apto 111 Jardim Paulista - CEP:01404-001 Sao Paulo direct-br@bilcare.com</p> <p>Bilcare 5-Eurong Street, Wahroonga, NSW 2076 Sydney direct-au@bilcare.com</p>	<p>Argentina</p> <p>Bangladesh</p> <p>Chile</p> <p>Colombia</p> <p>Czech Republic</p> <p>Egypt</p> <p>France</p> <p>Indonesia</p> <p>Iran</p> <p>Israel</p> <p>Jordan</p> <p>Korea</p> <p>Malaysia</p> <p>Mexico</p> <p>Pakistan</p> <p>Saudi Arabia</p> <p>South Africa</p> <p>Spain</p> <p>Taiwan</p> <p>Thailand</p> <p>Turkey</p> <p>Venezuela</p> <p>Vietnam</p>

© 2009, Bilcare Limited. All Rights Reserved.

FORWARD LOOKING STATEMENTS: This fact sheet is neither an offer nor solicitation to buy or sell any securities mentioned and is for educational purposes only. While it is believed all sources of information are factual and reliable, in no way is it represented or guaranteed that the description or statements herein are accurate and complete. The reader should verify all claims and do his/her/their own due diligence before investing in any securities mentioned. Any forward-looking statements involve risks and uncertainties. Bilcare Research does not undertake any obligation to update any forward looking statement, except as required under applicable law. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent of Bilcare Limited. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.